Beromun (tasonermin) / Boehringer Ingelheim - LARVOL DELTA

NivoILP: Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion (clinicaltrials.gov) - P1/2 | N=74 | Recruiting | Sponsor: Vastra Gotaland Region | Trial completion date: Dec 2027 ➔ Dec 2029 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor

NivoILP: Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion (clinicaltrials.gov) - P1/2 | N=74 | Recruiting | Sponsor: Sahlgrenska University Hospital, Sweden | Trial completion date: Dec 2025 ➔ Dec 2027 | Trial primary completion date: Dec 2023 ➔ Dec 2025

Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor

NivoILP: Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion (clinicaltrials.gov) - P1/2 | N=74 | Recruiting | Sponsor: Sahlgrenska University Hospital, Sweden | Trial completion date: Dec 2023 ➔ Dec 2025 | Trial primary completion date: Dec 2021 ➔ Dec 2023

Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor

Neoadjuvant Hypertermic Isolated Limb Perfusion in Treatment of Undifferentiated Spindle Cell Sarcoma of Lower Limb with Achieved Complete Pathologic Response. (PubMed, Klin Onkol) - "Hyperthermic isolated limb perfusion with tasonermin and melphalan is an important part of a multimodal approach in the treatment of extremity sarcomas with a high percentage of responses that increase the percentage of limbs retaining resections. Multidisciplinary team should consider this option in patients with localized limb sarcomas and should be performed in specialized centers with experience in this procedure. This work was supported by project Progres Q28-LF1. The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study. The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers."

Clinical • Journal